{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:27Z","timestamp":1790622987503,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10557-020-07090-x","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T06:03:01Z","timestamp":1602223381000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry"],"prefix":"10.1007","volume":"35","author":[{"given":"Despoina-Rafailia","family":"Benetou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Varlamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Ktenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsiafoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koutouzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bampali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zarifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Skalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Varvarousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Lianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kanakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Pisimisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Ziakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Davlouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of GRAPE-AF investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"7090_CR1","first-page":"195","volume":"14","author":"CA Morillo","year":"2017","unstructured":"Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14:195\u2013203.","journal-title":"J Geriatr Cardiol"},{"key":"7090_CR2","doi-asserted-by":"publisher","first-page":"1574541","DOI":"10.1080\/20016689.2019.1574541","volume":"7","author":"CI Coleman","year":"2019","unstructured":"Coleman CI, Briere JB, Fauchier L, Levy P, Bowrin K, Toumi M, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 2019;7:1574541.","journal-title":"J Mark Access Health Policy"},{"key":"7090_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","volume":"63","author":"E Michniewicz","year":"2018","unstructured":"Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - double trouble. Adv Med Sci. 2018;63:30\u20135.","journal-title":"Adv Med Sci"},{"key":"7090_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"7090_CR5","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40:3757\u201367.","journal-title":"Eur Heart J"},{"key":"7090_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","volume":"138","author":"DJ Angiolillo","year":"2018","unstructured":"Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective-2018 Update. Circulation. 2018;138:527\u201336.","journal-title":"Circulation."},{"key":"7090_CR7","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140:e125\u201351.","journal-title":"Circulation."},{"key":"7090_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization [published correction appears in Eur Heart J. 2019 Oct 1;40(37):3096]. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"7090_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10557-018-6789-7","volume":"32","author":"I Xanthopoulou","year":"2018","unstructured":"Xanthopoulou I, Dragona VM, Davlouros P, et al. Contemporary antithrombotic treatment in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: rationale and design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Cardiovasc Drugs Ther. 2018;32:191\u20136.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7090_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324.","journal-title":"N Engl J Med"},{"key":"7090_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.pcad.2018.01.010","volume":"60","author":"MB Effron","year":"2018","unstructured":"Effron MB, Gibson CM. Dual (anticoagulant plus single antiplatelet) vs triple (anticoagulant plus dual antiplatelet) antithrombotic therapy - \"real world\" experience. Prog Cardiovasc Dis. 2018;60:531\u20136.","journal-title":"Prog Cardiovasc Dis"},{"key":"7090_CR12","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","volume":"72","author":"C Sindet-Pedersen","year":"2018","unstructured":"Sindet-Pedersen C, Lamberts M, Staerk L, Nissen Bonde A, Berger JS, Pallisgaard JL, et al. Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease. J Am Coll Cardiol. 2018;72:1790\u2013800.","journal-title":"J Am Coll Cardiol"},{"key":"7090_CR13","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"7090_CR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"7090_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1536\/ihj.19-127","volume":"60","author":"A Horiguchi","year":"2019","unstructured":"Horiguchi A, Fukaya H, Oikawa J, Shirakawa Y, Kobayashi S, Arakawa Y, et al. Real-world antithrombotic therapy in atrial fibrillation patients with a history of percutaneous coronary intervention. Int Heart J. 2019;60:1321\u20137.","journal-title":"Int Heart J"},{"key":"7090_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.amjcard.2019.11.029","volume":"125","author":"JM Ten Berg","year":"2020","unstructured":"Ten Berg JM, Steg PG, Bhatt DL, et al. Comparison of the effect of age (< 75 versus \u2265 75) on the efficacy and safety of dual therapy (dabigatran + clopidogrel or ticagrelor) versus triple therapy (warfarin + aspirin + clopidogrel or ticagrelor) in patients with atrial fibrillation after percutaneous coronary intervention (from the RE-DUAL PCI trial). Am J Cardiol. 2020;125:735\u201343.","journal-title":"Am J Cardiol"},{"issue":"5","key":"7090_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/clc.22949","volume":"41","author":"A Buchholz","year":"2018","unstructured":"Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagres N, et al. Initial apixaban dosing in patients with atrial fibrillation. Clin Cardiol. 2018;41(5):671\u20136.","journal-title":"Clin Cardiol"},{"key":"7090_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335\u201343.","journal-title":"Lancet."},{"key":"7090_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/europace\/euz259","volume":"22","author":"TS Potpara","year":"2020","unstructured":"Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials [published correction appears in Europace. 2020 Feb 1;22(2):176]. Europace. 2020;22:33\u201346.","journal-title":"Europace."},{"key":"7090_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10557-019-06916-7","volume":"33","author":"D Alexopoulos","year":"2019","unstructured":"Alexopoulos D, Mpahara A, Kassimis G. Omitting aspirin in PCI patients: myth or reality? Cardiovasc Drugs Ther. 2019;33:711\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7090_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","volume":"4","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019;4:747\u201355.","journal-title":"JAMA Cardiol"},{"issue":"20","key":"7090_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","volume":"141","author":"JH Alexander","year":"2020","unstructured":"Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141(20):1618\u201327.","journal-title":"Circulation."},{"key":"7090_CR23","doi-asserted-by":"publisher","first-page":"ehaa575","DOI":"10.1093\/eurheartj\/ehaa575","volume":"2020","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [published online ahead of print, 2020 Aug 29]. Eur Heart J. 2020;2020:ehaa575.","journal-title":"Eur Heart J"},{"key":"7090_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"7090_CR25","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"7090_CR26","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, et al. Ticagrelor or Prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524\u201334.."},{"key":"7090_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","volume":"45","author":"TA Nguyen","year":"2005","unstructured":"Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"7090_CR28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, ten Berg J, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521\u201337.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"7090_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4244\/EIJ-D-18-00995","volume":"15","author":"A Goedel","year":"2019","unstructured":"Goedel A, Fiedler KA, Mehilli J, Bernlochner I, von Olshausen G, Mayer K, et al. Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. EuroIntervention. 2019;15(8):700\u20136.","journal-title":"EuroIntervention."},{"issue":"2","key":"7090_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11239-016-1350-7","volume":"42","author":"CB Olivier","year":"2016","unstructured":"Olivier CB, Weik P, Meyer M, Weber S, Diehl P, Bode C, et al. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. J Thromb Thrombolysis. 2016;42(2):161\u20136.","journal-title":"J Thromb Thrombolysis"},{"key":"7090_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10557-018-6795-9","volume":"32","author":"I Andreou","year":"2018","unstructured":"Andreou I, Briasoulis A, Pappas C, Ikonomidis I, Alexopoulos D. Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2018;32:287\u201394.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7090_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/heartjnl-2019-315963","volume":"106","author":"F Lupercio","year":"2020","unstructured":"Lupercio F, Giancaterino S, Villablanca PA, Han F, Hoffmayer K, Ho G, et al. P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. Heart. 2020;106:575\u201383.","journal-title":"Heart."},{"key":"7090_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ahj.2019.05.003","volume":"214","author":"A Mentias","year":"2019","unstructured":"Mentias A, Shantha G, Adeola O, Barnes GD, Narasimhan B, Siontis KC, et al. Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: a Medicare analysis. Am Heart J. 2019;214:158\u201366.","journal-title":"Am Heart J"},{"key":"7090_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007444","volume":"7","author":"T Pol","year":"2018","unstructured":"Pol T, Held C, Westerbergh J, et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. J Am Heart Assoc. 2018;7:e007444.","journal-title":"J Am Heart Assoc"},{"key":"7090_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/clc.22583","volume":"39","author":"J Abtan","year":"2016","unstructured":"Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, et al. Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH registry. Clin Cardiol. 2016;39:670\u20137.","journal-title":"Clin Cardiol"},{"key":"7090_CR36","doi-asserted-by":"publisher","unstructured":"Benetou DR, Varlamos C, Mpahara A, et al. Double or triple antithrombotic treatment in atrial fibrillation patients with acute myocardial infarction undergoing percutaneous coronary intervention [published online ahead of print, 2020 Mar 14]. Am J Cardiovasc Drugs. 2020. https:\/\/doi.org\/10.1007\/s40256-020-00403-3.","DOI":"10.1007\/s40256-020-00403-3"},{"key":"7090_CR37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ajh\/hpx135","volume":"30","author":"MA Esteve-Pastor","year":"2017","unstructured":"Esteve-Pastor MA, Rivera-Caravaca JM, Lip GYH. Hypertension and atrial fibrillation: balancing stroke and bleeding risks. Am J Hypertens. 2017;30:1063\u20135.","journal-title":"Am J Hypertens"},{"key":"7090_CR38","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","volume":"74","author":"MJ Sarnak","year":"2019","unstructured":"Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:1823\u201338.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7090_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12916-018-1145-0","volume":"16","author":"A Covic","year":"2018","unstructured":"Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, et al. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med. 2018;16(1):158.","journal-title":"BMC Med"},{"key":"7090_CR40","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1016\/j.ijcard.2013.08.007","volume":"168","author":"D Alexopoulos","year":"2013","unstructured":"Alexopoulos D, Goudevenos JA, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, et al. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol. 2013;168:5329\u201335.","journal-title":"Int J Cardiol"},{"key":"7090_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2016.03.030","volume":"69","author":"J Goudevenos","year":"2016","unstructured":"Goudevenos J, Xanthopoulou I, Deftereos S, et al. One-year non-persistence with contemporary antiplatelet therapy in acute coronary syndrome patients undergoing percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed). 2016;69:790\u20133.","journal-title":"Rev Esp Cardiol (Engl Ed)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07090-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T18:55:16Z","timestamp":1669143316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07090-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["7090"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07090-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"1 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by each institution\u2019s human research committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Skalidis has received lecturing honoraria\/advisory board fees from Astrazeneca, Bayer, Boehringer Ingelheim, Medtronic. Dr. Pisimisis has received advisory board fees from Astrazeneca. Dr. Ziakas has received lecturing fees from Astrazeneca. Dr. Alexopoulos has received lecturing honoraria\/advisory board fees from Astrazeneca, Bayer, Boehringer Ingelheim, Pfizer, Medtronic, Biotronik, Chiesi Hellas. Other authors have no disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable. No identifying information about participants is available in the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}